Michael Georgetson, MD

Guthrie Provider
Care Provider Overall: 
5
Provider Reviews: 
76

Call for an appointment
866-GUTHRIE (866-488-4743)

  • Clinical Details
  • Education
  • News & Video
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Corning Hospital
  • Guthrie Robert Packer Hospital
  • Guthrie Troy Community Hospital
Clinical Interests: 
  • Dysphagia
  • ERCP
  • Esophageal Diseases
  • Gastrointestinal Bleeding
  • Gastrointestional Neoplasia

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • Robert Packer Hospital, Sayre, Pa.
Certification: 
  • American Board of IM/Gastroenterology
Education: 
  • Jefferson Medical College, Philadelphia, Pa.
Fellowship: 
  • Robert Packer Hospital, Sayre, Pa.
  • Fellow of the American College of Gastroenterology (FACG)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Summit
Details (Identifier #): NCT03595566
Title: Protocol SMT19969/C005 (Ri-CoDIFy 2): A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Seres
Details (Identifier #): NCT03183128
Title: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults (SERES-012)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Seres
Details (Identifier #): NCT03183141
Title: ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT03653026
Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT02819635
Title: AbbVie M14-234, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT03006068
Title: M14-533, A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Boehringer Ingelheim Phar
Details (Identifier #): NCT03482635
Title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in Patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy
Department: Gastroenterology
Diagnosis: Gastrointestinal - GERD
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Ironwood
Details (Identifier #): NCT03561883
Title: C3718-302, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT03599622
Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease
Department: Gastroenterology
Diagnosis: Gastrointestinal - Gastric (Stomach)
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Allergan
Details (Identifier #): NCT03426345
Title: RLM-MD-02, A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Allergan
Details (Identifier #): NCT03383146
Title: RLM-MD-04: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: November 2019
Was very prompt on getting me scheduled for my operation. Working with other doctors.
Guthrie Patient: November 2019
He even laughed at my goofy comments about his name. He had a good bedside manner.
Guthrie Patient: November 2019
Dr. Georgetsoin is a class act and the entire staff was very professional and patient centric
Guthrie Patient: November 2019
Dr. Georgetson went above and beyond patiently took time to explain my procedure did not seem rushed, very attentive, kind doctor. I felt well and well cared for after my procedure...the nurse anesthetist did a great job was very nice, as were the RNs I dealt with afterward. My entire procedure was one I would recommend to anyone to have at Guthrie.
Guthrie Patient: November 2019
Dr. Georgetson shows a lot of concern for my problems
Guthrie Patient: November 2019
wonderful
Guthrie Patient: October 2019
Excellent provider. Try to keep him - too much turn over in the clinic.
Guthrie Patient: October 2019
*Dr. Georgetson is great w/ a great personality. I would highly recommend him.
Guthrie Patient: October 2019
Dr Georgeston is AWESOME !!!!!You guys more doctors like him that actually takes the time with the patient. Never is in a hurry and always makes sure you understand everything. Plan and simple, I won't see any other doctor in that department other than Georgeston.
Guthrie Patient: October 2019
Dr. Georgetson is inclusive and kind. He remembers me the person. He is building a great team and his efforts are coming to fruition